Vertex Pharmaceuticals Incorporated today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the ...
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 ...
Janus Henderson Global Life Sciences Fund returned 8.26% and the MSCI World Health Care Index returned 3.01%. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback